The low–molecular-weight heparin enoxaparin is a safe and effective therapy to prevent symptomatic venous thromboembolism in patients undergoing chemotherapy for advanced pancreatic cancer, according ...
Among over 17,000 patients, the more selective enoxaparin protocol was associated with a reduction in wound hematomas compared with the original standard protocol (0.3% vs 0.7%; adjusted OR 0.38, 95% ...
NEW ORLEANS, LA—Rivaroxaban is non-inferior to enoxaparin in short-term use and superior in long-term use for the prevention of venous thromboembolism (VTE) in acutely ill medical patients, but ...
Oral edoxaban showed superior results to subcutaneous enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty, according to findings published in Thrombosis Journal. “In ...
(HealthDay News) — Once-daily enoxaparin is associated with fewer major bleeds than enoxaparin twice daily in patients with acute venous thromboembolism (VTE), according to a study published online in ...
In the Prevention of VTE in Acutely ill Patients, Rivaroxaban Compares Favorably with Enoxaparin but Does Not Show a Consistent Net Clinical Benefit MAGELLAN study meets primary efficacy endpoints of ...
Aspirin alone doesn’t seem to be enough to prevent symptomatic venous thromboembolism (VTE) in the months following total hip or knee replacement for osteoarthritis, results of the CRISTAL trial ...
In the randomized, placebo-controlled EXCLAIM trial, Russell Hull and colleagues evaluated the efficacy and safety of extended-duration enoxaparin (low-molecular-weight heparin). A large proportion of ...
In this study, no difference in the rate of CVC-related VTE was detected between patients receiving enoxaparin and patients receiving placebo. The dose of enoxaparin used in this study proved to be ...
Extended use of betrixaban beyond the usual period of parenteral prophylaxis with enoxaparin reduced venous thromboembolism (VTE) incidence among medically ill patients. WASHINGTON, DC—Extended use of ...
Oral rivaroxaban (Xarelto; Bayer/Janssen) is superior to subcutaneous enoxaparin in preventing venous thromboembolism (VTE) without increasing bleeding in patients undergoing nonmajor orthopedic ...
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the results of the Phase 3 ADOPT (Apixaban Dosing to Optimize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback